Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

501 results about "Gout" patented technology

A type of arthritis that causes inflammation of joints due to excess uric acid.

Probiotics plant solid beverage for treating hyperuricemia and gout

InactiveCN110623182Apreserve nutritional valuedisease resistantSkeletal disorderFood ingredient as taste affecting agentFreeze-dryingCelery seeds
The invention provides a probiotics plant solid beverage for treating hyperuricemia and gout. The solid beverage is prepared by mixing freeze-dried probiotics powder and plant extract with the addition of proper auxiliary materials. The solid beverage comprises the following components: the plant extract, the auxiliary materials and the probiotics, with the sum of the mass percentage of each component being 100%. The plant extract comprises celery seed powder, sophora flower bud powder and platycodon root powder. The invention has an obvious effect on lowering uric acid and relieving gout.
Owner:胡洁

Substituted piperidinediones for targeted protein degradation

PCT designated stage expiredWO2025024521A1Organic active ingredientsAntipyreticInterstitial lung diseasePericarditis
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrade and / or otherwise modulate (e.g., inhibit) NIMA Related Kinase 7 (NEK7). Said chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having one or more disorders or diseases associated with NLRP3 inflammasome activation. Said disorders or diseases include but are not limited to, autoinflammatory and autoimmune disorders (e.g., gout, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease), cardiovascular and metabolic disorders (eg. pericarditis, atherosclerosis, Type 2 diabetes, obesity, and metabolic syndrome), fibrotic disorders (e.g. interstitial lung disease, chronic kidney disease), hematology (eg. anemia of inflammation) and eye disorders (eg. macular degeneration). In embodiments, and while not wishing to be bound by theory, it is believed that the chemical entities described herein directly target (e.g., directly bind to) NEK7, thereby altering (e.g., attenuating) the inflammatory response modulated by the NLRP3 inflammasome. This disclosure also features compositions containing the same as well as methods of using and making the same.
Owner:MONTE ROSA THERAPEUTICS AG

Gout detection hearing aid system for monitoring uric acid level in real time by using sweat sensor

The embodiment of the invention discloses a gout detection hearing aid system for monitoring uric acid level in real time by using a sweat sensor, and relates to the technical field of hearing aid devices and algorithms. The hearing aid system comprises a hearing aid, a processor and a processor, the outer side of the flexible sweat sensor patch is used for being attached to the skin behind the ear, the inner side of the flexible sweat sensor patch is attached to the outer surface of the hearing aid, and the flexible sweat sensor patch is electrically connected with the hearing aid chip through a contact electrode; sweat of the skin behind the ear flows into the micro-channel through the sweat collecting hole, after an electric field is applied to the detection electrode, the level of uric acid in the micro-channel is measured through the Raman spectrum technology, and the uric acid is transmitted to the interior of the hearing-aid chip to be processed. And the disease monitoring system is used for recording detection data, analyzing gout risks and linking the hearing aid to carry out in-ear early warning when the data is abnormal. The system is noninvasive and portable, and can solve the problem of user hearing and gout management at the same time.
Owner:HANGZHOU HUIER HEARING INSTR & TECH CO LTD

Application of eupatorium chinense extract in preparation of medicine for treating gout

The invention belongs to the technical field of medicines, and particularly relates to application of eupatorium chinense extract in preparation of a medicine for treating gout. Researches show that the eupatorium chinense extract and the active components thereof have good biological activity and can inhibit the activity of xanthine oxidase (XOD). Molecular docking experiments also show that the eupatorium chinense extract and xanthine oxidase have good binding energy. Further research finds that the eupatorium chinense extract can reduce the levels of uric acid and creatinine in serum in a hyperuricemia mouse body, and has good uric acid reducing activity. In the field of treatment of hyperuricemia and gout, many traditional medicines have many adverse reactions. Compared with the prior art, the eupatorium chinense serving as a traditional Chinese medicine provides a safe and effective natural medicine for treating hyperuricemia and gout or gout complications due to the efficient uric acid reducing effect of the eupatorium chinense.
Owner:CHINA THREE GORGES UNIV

Abdominal distention hippocampal peptide and application thereof in preparation of uric acid reducing and gout resisting products

The invention relates to the field of preparation and application of biological peptides, in particular to a swelling hippocampal peptide and application thereof in preparation of uric acid reducing and gout resisting products. The amino acid sequence is shown as SEQ ID NO.1. The uric acid reducing effect of the compound is proved through in-vitro xanthine oxidase (XOD) and adenosine deaminase (ADA) inhibition experiments and cell experiments; on the basis, the uric acid reducing and gout resisting activity of the peptide sequence is further verified by means of a hyperuricemia animal model. The achievement provides a solid theoretical support for high-value development and utilization of the hippocampus japonicus and research and development of uric acid reducing and gout resisting related products.
Owner:OCEAN UNIV OF CHINA

Formulations and doses of pegylated uricase

Provided herein are methods and compositions and kits related to uricase compositions and / or compositions comprising synthetic nanocarriers comprising an immunosuppressant. Also provided herein are methods and compositions and kits for the treatment of subjects, including subjects with hyperuricemia, gout or a condition associated with gout, and for preventing gout flare.
Owner:CARTESIAN THERAPEUTICS INC

Preparation method and application of medicinal and edible composition for reducing uric acid and treating gout

The invention discloses a preparation method and application of a medicinal and edible composition for reducing uric acid and treating gout, and belongs to the crossing field of medicine and food technologies. The composition is composed of celery seeds, sophora flower buds, chicory, dandelion, mulberry twigs, pawpaw and fresh lalang grass rhizomes, all the components have a synergistic effect, and the effects of inhibiting generation of uric acid, promoting excretion of uric acid, resisting inflammation, diminishing swelling and adjusting body metabolism at multiple target points are achieved. The preparation method comprises the steps of intelligent screening and fine pretreatment of raw materials, a multi-stage targeted extraction process and intelligent concentration and precise forming, and active ingredients can be efficiently extracted and prepared into various dosage forms. According to the composition, in the aspect of precise medical assistance, personalized medication schemes are customized according to different stages of gout, and whole-course digital management is achieved by means of intelligent equipment and a cloud platform; in daily smart health care of families, gout prevention of the families is facilitated through smart home kitchen equipment and a uric acid monitoring set; the method is used for innovative health food development, and provides a new natural, efficient and multifunctional health management approach for gout patients.
Owner:SHANDONG RENYITANG BIOTECHNOLOGY CO LTD

Traditional Chinese medicine composition for treating gout and auxiliary device thereof

The invention provides a traditional Chinese medicine composition for treating gout and a preparation auxiliary device.The traditional Chinese medicine composition comprises liquorice, astragalus membranaceus, semen plantaginis, lysimachia christinae hance, cibotium barometz and oriental wormwood, and the medicine properties of the traditional Chinese medicine composition for treating the gout are slightly cold, bitter and pungent in taste and free of toxic and side effects. Besides being used for treating gout symptoms, the traditional Chinese medicine also has the effects of inducing diuresis, clearing heat and promoting diuresis, removing jaundice, clearing liver and improving vision, clearing lung and eliminating phlegm and the like. Besides, in the process that the extraction liquid and the solid residues are separated through rotation of the centrifugal cylinder in the auxiliary device, a balance weight plate and a pressing plate are thrown outwards under the action of centrifugal force at the same time till the fixed residues are pressed to the side wall of the classification barrel, extrusion on the solid residues is formed, the extraction liquid permeating into the solid residues is fully extruded out, and the solid residues are separated. The extraction amount of an extraction liquid formed by extracting the traditional Chinese medicine composition is increased, and waste is avoided.
Owner:XIAMEN FUCIHAI TRADING CO LTD

Abdominal distention hippocampal peptide and application thereof in preparation of uric acid reducing and gout resisting products

The invention relates to the field of preparation and application of biological peptides, in particular to a swelling hippocampal peptide and application thereof in preparation of uric acid reducing and gout resisting products. The amino acid sequence is shown as SEQ ID NO.1-5. The uric acid reducing effect is verified by adopting an in-vitro XOD inhibition experiment and a cell experiment; furthermore, the uric acid reducing and gout resisting activity of the compound is verified through a hyperuricemia animal model, and a theoretical basis is provided for high-valued utilization of the belly-swelling hippocampus and development of uric acid reducing and gout resisting products.
Owner:OCEAN UNIV OF CHINA

Application of xanthohumol in preparation of drugs for reducing uric acid and resisting gout

The invention relates to the technical field of medicines, in particular to application of an active ingredient xanthohumol (XAN) derived from a traditional Chinese medicine humulus lupulus in preparation of medicines for reducing uric acid and resisting gout, and the xanthohumol (XAN) can be prepared into various oral preparations, injection preparations and external preparations with the assistance of pharmaceutically acceptable auxiliary materials and has good development and application prospects. The inventor finds that the xanthohumol has relatively strong effects of reducing blood uric acid, resisting inflammation, resisting bone damage and the like, and the mechanism of the effect of reducing the blood uric acid is that the activity of xanthine oxidase is inhibited so as to reduce the generation of uric acid, and the renal function of an organism is improved so as to enhance uric acid excretion; according to the anti-inflammatory effect, the inflammatory reaction is relieved mainly by down-regulating the levels of inflammatory factors such as IL-1beta, IL-6, TNF alpha and PEG2; the mechanism for resisting gout bone damage is realized through the fact that RANKL / OPG / RANK signal pathway participates in bone metabolism regulation.
Owner:THE NAVAL MEDICAL UNIV OF PLA

A method for establishing a hyperuricemia prediction model using machine learning algorithms

The present invention provides a method for establishing a hyperuricemia prediction model using a machine learning algorithm, which belongs to the field of health assessment technology. The embodiment of the present invention uses a UKBB cohort based on a large population as training, and uses an internal test set and a dataset of healthy physical examinees from Southern Hospital as an external test set to establish and verify a reliable and practical stacked multimodal machine learning model trained based on genetic and clinical data, which is used to timely identify HUA phenotypes and early predict gout and metabolic-related outcome risks. The model has excellent performance, exceeding each single machine learning model, and shows satisfactory efficacy. The ISHUA marker can quantify gout risk and metabolic-related results at an early stage, can provide active guidance for daily health examinations and the management of risk factors, and provide valuable information support for clinicians to appropriately manage HUA risk factors after routine health screening.
Owner:NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV

Gout diagnosis and recurrence risk prediction method and system based on Raman spectrum and multi-modal machine learning

The invention provides a gout diagnosis and recurrence risk prediction method and system based on Raman spectrum and multi-modal machine learning, and the method comprises the steps: generating a Raman spectrum sample data set, and carrying out the preprocessing; performing data dimension reduction and feature extraction on the preprocessed Raman spectrum sample data set to obtain key feature vectors; performing feature screening and enhancement on the key feature vectors before modeling; modeling the data before and after dimension reduction by using a machine learning algorithm to obtain a plurality of machine learning models; and training the multiple machine learning models by using a training set, verifying the models by using a ten-fold cross validation method, selecting the machine learning model with the best discrimination effect as a prediction model, and performing risk prediction of medical history development and gout recurrence. The Raman spectrum and the advanced artificial intelligence technology are integrated, a new prospect is provided for identifying unique metabolic characteristics related to the diseases, the clinical management level of gout is improved, and intervention is earlier and more accurate.
Owner:NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV

Application of indole-3-lactic acid in preparation of uric acid reducing product

The invention provides application of indole-3-lactic acid in preparation of uric acid reducing products, and relates to the technical field of medicines. The indole-3-lactic acid is found to have a good blood uric acid reducing effect for the first time, a new uric acid reducing medicine component is provided for health-care food, hyperuricemia and related diseases thereof, and the indole-3-lactic acid is small in renal function damage and is a safe and efficient uric acid reducing functional component. The gout treatment mechanism of the indole-3-lactic acid is mainly realized by relieving the inflammatory response of the organism and improving uric acid excretion, and the indole-3-lactic acid has dual effects, is different from the mechanism of the existing medicine, and has unique innovation.
Owner:XIANGAN HOSPITAL AFFILIATED TO XIAMEN UNIV

Lactobacillus buchneri complex microbial inoculant and application thereof

The invention discloses a lactobacillus buchneri complex microbial inoculant and application thereof, and belongs to the technical field of microorganisms. In order to solve the problem of poor direct degradation effect of lactic acid bacteria on uric acid in the prior art, the invention provides a complex microbial inoculant containing lactobacillus buchneri NEFU-1 and NEFU-2, and the complex microbial inoculant has the functions of degrading uric acid, relieving hyperuricemia, degrading inosine and / or guanosine, improving intestinal flora composition and reducing inflammatory factors; the lactobacillus plantarum has important significance on preventing, improving and treating gout and hyperuricemia diseases, has high application value and can be applied to preparation of fermented yoghurt.
Owner:NORTHEAST FORESTRY UNIV

Preparation method of medicinal external washing liquid medicine for treating gout

The invention relates to the technical field of traditional Chinese medicine, and discloses a preparation method of a medicinal external washing liquid for treating gout, the medicinal external washing liquid is prepared from the following raw material medicines by weight: 20 g of pseudo-ginseng, 28 g of sweet wormwood, 14 g of bauhinia championii, 24 g of kadsura longipedunculata, 12 g of gastrodia elata, 9 g of divaricate saposhnikovia root, 7 g of cornu cervi pantotrichum, 30 g of radix clematidis, 20 g of ipomoea batatas, 30 g of caulis spatholobi, 17 g of soft tendon and 25 g of angelica sinensis. The traditional Chinese medicine composition has the advantages that the effects of eliminating swelling and gout stones are achieved, and the side effect of liver and kidney injury caused by western medicines is reduced.
Owner:HAIKOU WORLD BANK INVESTMENT CO LTD

Application of sugarcane polyphenol extract in preparation of medicine for preventing and / or treating hyperuricemia

The invention relates to an application of a sugarcane polyphenol extract in preparation of a medicine for preventing and / or treating hyperuricemia. The invention also discloses application of the sugarcane polyphenol extract in medicines or health care products for gout caused by hyperuricemia, chronic gout, liver injury and kidney injury. The technical problem to be solved is how to provide the sugarcane polyphenol extract, the sugarcane polyphenol extract contains at least 32 polyphenol monomers, the uric acid reducing effect is improved through the synergistic effect among the polyphenol monomers, and the sugarcane polyphenol extract can be used for preparing drugs or health care products for preventing and / or treating hyperuricemia.
Owner:PURUOWEIKE (SUZHOU) BIOTECHNOLOGY CO LTD

Preparation method and application of biomarker sensor for monitoring sweat gout

The invention discloses a preparation method and application of a biomarker sensor for monitoring sweat gout. According to the scheme, an Au sensing electrode is prepared on the surface of a flexible polyethylene glycol terephthalate (PET) thin film in a patterning manner by utilizing an evaporation technology, and a polypyrrole functional layer is prepared on the surface of the electrode by virtue of a molecular imprinting technology; the gout biomarker high-sensitivity detection sensor is constructed in an efficient and rapid manner; the sensor can effectively identify uric acid and xanthine in sweat and display the concentration level of the uric acid and the xanthine, and can provide real-time sensing service for prevention of gout diseases and monitoring of diagnosis and treatment processes of patients with hyperuricemia and yellow urine diseases; a scanning electron microscope is used for carrying out microtopography characterization on the molecularly imprinted functional layer, and an electrochemical workstation is used for carrying out sensing recognition performance characterization. The sensor has the characteristics of rapid identification, convenient sensing and wide detection range for biomarkers of gout, hyperuricemia and yellow urine.
Owner:NANJING UNIV OF POSTS & TELECOMM

Application of marker combination in prediction or diagnosis of gout

The invention discloses an application of a marker combination in prediction or diagnosis of gout, the marker combination comprises an immune cell subset and clinical data, and the immune cell subset comprises virus-specific cytotoxic NK cells and inhibitory Vdelta2 cells. The marker combination comprises immune cell subgroups and clinical data, different immune cell subgroups are matched with different clinical data when a gout attack stage and a gout remission stage are distinguished, or when the gout remission stage and a healthy subject are distinguished, and high-sensitivity and high-specificity diagnosis results are achieved. Therefore, the marker combination disclosed by the invention has a wide prospect in the aspect of predicting different processes of gout, and can provide more basic research data for health management of gout high-risk people.
Owner:SHANGHAI TENTH PEOPLES HOSPITAL +1

Oral solid preparation for treating gout and preparation method thereof

The invention relates to the technical field of pharmaceutical preparations, and provides an oral solid preparation for treating gout and a preparation method thereof. The preparation method comprises the following steps: sieving a filling agent, a disintegrating agent, an adhesive and dotenorad to obtain a sieved material; and mixing the sieved material and a lubricant, and tabletting to obtain the oral solid preparation for treating gout, the filling agent is lactose, mannitol and microcrystalline cellulose. By optimizing the prescription and the preparation process, the dissolution rate and bioavailability of the medicine are improved, so that the curative effect is improved; by selecting proper auxiliary materials and preparation types, the stimulation to gastrointestinal tracts is reduced, and the tolerance of patients is improved; the oral solid preparation is convenient to take, accurate in dosage, high in patient compliance and beneficial to long-term treatment; moreover, the preparation method provided by the invention is simple to operate, easy for industrial production and relatively low in cost.
Owner:SHANDONG INOMIC INST OF PHARM RES CO LTD

Application of conjugated ketene skeleton bromophenol compound in preparation of anti-gout drugs

The invention discloses an application of a conjugated ketene skeleton bromophenol compound in preparation of an anti-gout drug, the conjugated ketene skeleton bromophenol compound comprises BP-50 and BP-47, and experiments prove that the conjugated ketene skeleton bromophenol compound has remarkable inhibitory activity on xanthine oxidase, and can be used for preparing anti-gout drugs. The invention further studies the inhibition effect of the conjugated ketene skeleton bromophenol compound on MSU-induced inflammation taking NLRP3 inflammasome as a core, both BP-50 and BP-47 can inhibit secretion of MSU-induced characteristic inflammatory factors IL-1beta in a concentration-dependent manner, BP-50 down-regulates expression of NLRP3 inflammasome components by inhibiting an MAPK / NF-kappa B signal channel, and BP-47 can inhibit MSU-induced inflammation taking NLRP3 inflammasome components by inhibiting MAPK / NF-kappa B signal channel. The activation of the NLRP3 inflammasome is inhibited by reducing the ROS content, so that the activity of the NLRP3 inflammasome is reduced. It is proved that the conjugated ketene skeleton bromophenol compound can be used for preparing the anti-gout medicine, has a remarkable technical effect and has a wide market application prospect.
Owner:OCEAN UNIV OF CHINA +1

Methods for the treatment of NLRP3 related disorders

Provided herein are methods for treating a disease or condition associated with one or more of: mtDNA fragmentation; cytostolic Ox-mtDNA; mtDNA release; or Casp1 activation and IL-1β production by administering an effective amount of an inhibitor of human flap endonuclease-1 (FEN1). These diseases include without limitation, an inflammatory or a neurodegenerative disease, such as Alzheimer's, disease, Parkinson's disease, atherosclerosis, NASH, asthma, inflammatory bowel disease, melanoma, metabolic pathologies, including obesity, type 2 diabetes, atherosclerosis, inflammatory bowel diseases, gout, and periodic fevers.
Owner:RGT UNIV OF CALIFORNIA

RBP4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout

The subject invention provides a method for treating a non-alcoholic fatty liver disease (NAFLD) disease in a subject afflicted therewith comprising administering to the subject a pharmaceutical composition comprising an amount of a compound which is a non-retinoid retinol-binding protein 4 (RBP4) antagonist effective to treat the subject, thereby treating the subject.The subject invention provides a method for treating gout in a subject afflicted therewith comprising administering to the subject a pharmaceutical composition comprising an amount of a compound which is a retinol-binding protein 4 (RBP4) antagonist effective to treat the subject, thereby treating the subject.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK

Decarboxycarnosine composite liposome and application thereof in preparation of products for reducing uric acid and dissolving tophus

The invention relates to the field of biological medicine, in particular to a decarboxylated carnosine composite liposome and application thereof in preparation of products for reducing uric acid and dissolving tophus. The decarboxylated carnosine composite liposome is formed by self-assembling raw materials including decarboxylated carnosine, alkaloid, flavone, a polygonum cuspidatum extract, p-coumaric acid, a liquorice extract, a semen coicis extract, a yam rhizome extract, a poria cocos extract and quercetin, and research proves that the decarboxylated carnosine composite liposome can reduce uric acid, dissolve ventilation stone and balance in-vivo acid-base balance; the composition inhibits xanthine oxidase from synthesizing uric acid, promotes uric acid excretion and intestinal tract movement in the body, repairs damaged liver and kidney cells, diminishes swelling, resists inflammation, relieves pain, prevents and treats hyperuricemia, relieves gout inflammation, reduces blood pressure and improves immunity.
Owner:新智杰(苏州)生物科技有限公司

Medicinal and edible traditional Chinese medicine capable of treating gout and hyperuricemia

InactiveCN119258182Apromote circulationReduce the level of inflammationSkeletal disorderFungi medical ingredientsBENINCASA HISPIDA FRUITPolyporus
The invention discloses a traditional Chinese medicine with homology of medicine and food and capable of treating gout and hyperuricemia, and belongs to the field of medicine. The medicinal and edible traditional Chinese medicine capable of treating gout and hyperuricemia is prepared from the following raw materials in parts by weight: 40 to 60g of rhizoma smilacis glabrae, 3 to 7g of rhizoma curcumae longae, 10 to 20g of herba taraxaci, 5 to 15g of herba plantaginis, 10 to 20g of rhizoma polygoni cuspidati, 10 to 20g of polyporus umbellatus, 3 to 7g of radix et rhizoma rhei and According to the traditional Chinese medicine with homology of medicine and food and capable of treating gout hyperuricemia, all the components cooperate with one another to achieve a synergistic effect, on one hand, metabolism can be promoted, blood circulation can be accelerated, microcirculation disturbance conditions can be improved, the tissue inflammation reaction degree can be relieved, and edema and other symptoms can be eliminated; on the other hand, the immune system can be adjusted, the body resistance is enhanced, complications are prevented, and clinical symptoms such as arthralgia and other adverse reactions can be improved.
Owner:HENAN MIAOCAO SPECIAL MEDICAL BIOTECHNOLOGY CO LTD

Uric acid-reducing food composition containing food-borne melanin

The invention relates to a food-borne melanin-containing uric acid-reducing food composition which is prepared by mixing 2-10 parts by weight of celery seed extract, 1-6 parts by weight of food-borne melanin and 0-5 parts by weight of astragalus extract, plays a role in reducing uric acid by inhibiting the activity of xanthine oxidase, and has a better effect of treating hyperuricemia and / or gout. The liver and kidney injury caused by hyperuricemia can be improved, the toxic and side effects are low, and the food can be eaten for a long time.
Owner:SHANXI MEDICAL UNIV

Gout recurrence prediction method, system, equipment and medium

The invention provides a gout recurrence prediction method, system and device and a medium. The method comprises the following steps: acquiring clinical data of gout co-disease patients during hospitalization from an electronic health recording system of a multi-center data set; processing the clinical data according to a standardization method, a minimum-maximum normalization method and a Yeo-Johnson transformation method to obtain candidate clinical features, and screening the extracted candidate clinical features by applying a plurality of feature selectors to screen out clinical features highly related to the gout co-disease recurrence risk; constructing a candidate gout recurrence prediction model for gout recurrence prediction by using a plurality of classifiers; screening the gout recurrence prediction candidate model to obtain a gout recurrence prediction model; acquiring clinical features of the patient; the gout recurrence risk of the patient is predicted according to the clinical features of the patient and the gout recurrence prediction model, the clinical features highly related to the gout co-disease recurrence risk can be accurately screened out, the efficient prediction model is constructed, and therefore reliable auxiliary decision support is provided for clinicians.
Owner:NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV

Food medicine for reducing blood uric acid and treating gout

A food medicine for reducing blood uric acid and treating gout is characterized in that celery seeds, celery, mulberry fruits, mulberry leaves, sea buckthorn fruit powder, dandelions, rhizoma polygonati, poria cocos and beach kidney grass serve as a basic formula; the auxiliary materials comprise one, several or all of a plurality of formula combinations of ramulus mori, lycium ruthenicum, radix puerariae, Chinese yam, clerodendranthus spicatus, lysimachia christinae hance, acanthopanax, anserine, astragalus membranaceus, purslane, herba cepbalanoplosis segeti, galangal, hovenia dulcis thunb, astragalus membranaceus, luteolin, uric acid-reducing edible probiotics and the like, and are used for treating hyperuricemia and gout.
Owner:SHANTOU JINHUO ENVIRONMENTAL PROTECTION & ENERGY SAVING TECH CO LTD

RBP4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout

The subject invention provides a method for treating a non-alcoholic fatty liver disease (NAFLD) disease in a subject afflicted therewith comprising administering to the subject a pharmaceutical composition comprising an amount of a compound which is a non-retinoid retinol-binding protein 4 (RBP4) antagonist effective to treat the subject, thereby treating the subject.The subject invention provides a method for treating gout in a subject afflicted therewith comprising administering to the subject a pharmaceutical composition comprising an amount of a compound which is a retinol-binding protein 4 (RBP4) antagonist effective to treat the subject, thereby treating the subject.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK